Karen M. McGuire, PhD

Karen McGuire, PhD, CEO and co-founder of BioMendics, discusses TAMES-02 phase 2 trial enrollment and a new blister burden end point in EBS.

Karen McGuire, PhD, CEO and co-founder of BioMendics, explains what fast track status means for the investigational treatment and details the drug's mechanism of action in EBS.

Karen McGuire, PhD, CEO and co-founder of BioMendics, discusses why epidermolysis bullosa simplex remains a difficult gene therapy target.

Karen McGuire, PhD, discusses TolaSure, a groundbreaking therapy targeting epidermolysis bullosa simplex, focusing on cellular repair and blister reduction.

BioMendics is advancing TolaSure in the TAMES-02 trial for EBS, aiming for rapid market access and potential expansion to other keratinopathies.

Karen McGuire, PhD, discusses innovative TolaSure for treating epidermolysis bullosa simplex, focusing on disease modification rather than symptom management.

Karen McGuire, PhD, discusses TAMES-02, a clinical trial evaluating TolaSure for Epidermolysis Bullosa Simplex.